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- CHANGES IN EUROPEAN GUIDELINES  
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SUMMARY – Changes in the diagnostic pathway for prostate cancer advised in the most recent 
Guidelines of the European Association of Urology bring many endeavors for everyday practice. 
Availability, costs and radiological expertise are still representing a challenge for the adoption of these 
guidelines in everyday clinical practice. In this article we discuss the current situation regarding these 
issues and future options.
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Introduction
There were more than 450,000 new cases of pros-
tate cancer (PC) and approximately 107,000 deaths in 
Europe in the year 2018 (1). Prostate cancer became 
the most common solid cancer and among three lead-
ing causes of mortality from malignancies.
Significant changes have been made in 2019 re-
garding the diagnosis of prostate cancer in the most 
recent Guidelines on Prostate Cancer of the European 
Association of Urology (EU) (2). Through the year 
2019, a new concept of prostate cancer screening has 
emerged also in the EAU Position paper (3). Both 
have significant impact on a daily urologists’ practice.
Diagnosis of prostate cancer
For many years, the standard pathway to diagnose 
prostate cancer and determine whether it needs to be 
treated was based on the results of a transrectal ultra-
sound guided (TRUS) biopsy. This involves multiple 
needle biopsies to sample tissue across the prostate and 
possibly detect any cancerous cells. A major disadvan-
tage of this approach, besides discomfort for the patient, 
was the possibility to miss significant cancer if the part 
of the prostate with cancer isn’t sampled. Also, there 
was a risk of serious infection. This diagnostic pathway 
for prostate cancer has resulted in overdiagnosis and 
consequent overtreatment as well as underdiagnosis 
and missed diagnoses in many men. Finding a way to 
improve the number of significant prostate cancers 
that get caught in time, whilst reducing the number of 
men who have biopsies unnecessarily, became ex-
tremely important. Multiparametric MRI (mp-MRI) 
of the prostate has been identified as a test that could 
mitigate both diagnostic errors as well as ensuring that 
the biopsies are able to be much more targeted to 
where the cancer is actually located in the prostate (4).
The European Association of Urology (EAU) 
Guidelines on Prostate Cancer recommended per-
forming prostate mp-MRI before repeated (second) 
biopsy in 2014. The reason for this change appeared 
after tremendous work done by the group from the 
University/College of London (5). Their later land-
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mark study PROMIS was the first study that present-
ed blinded data on diagnostic accuracy of both mp-
MRI and TRUS-biopsy against an accurate reference 
test in biopsy-naive men with a suspicion of prostate 
cancer (6). It was a level 1b evidence for assessment of 
diagnostic accuracy. The main findings suggested that 
if mp-MRI was used as a triage test, one-quarter of 
men might safely avoid prostate biopsy. The high neg-
ative predictive value implied that mp-MRI would not 
miss many clinically significant cancers. Furthermore, 
over-diagnosis of clinically insignificant cancers might 
be reduced while detection of clinically significant 
cancers improved compared with the standard of 
TRUS-biopsy.
Once the role of mp-MRI against TRUS guided 
biopsy was elucidated, special attention was given to 
biopsy-naive man that might have prostate cancer. 
Three prospective studies evaluated MRI-TBx in biop-
sy-naive patients: PRECISION, MRI-FIRST trial 
and The Met Prostaat MRI Meer Mans (4M) study (7, 
8,9). PRECISION (Prostate Evaluation for Clinically 
Important Disease: Sampling Using Image guidance or 
Not?) was a multicenter study designed to determine 
whether a diagnostic MRI could be used instead of bi-
opsy to rule out prostate cancer. It included 500 men 
suspected of having prostate cancer after PSA testing. 
They either received an ultrasound-guided biopsy or 
MRI without biopsy. Men who had abnormal findings 
on MRI then went on to have targeted biopsy (7).
There was a 12 percent absolute improvement in 
the rate of cancer detection for those who had MRI 
prior to biopsy and MRI targeted biopsy compared to 
men who just had ultrasound-guided biopsy, while 28 
percent of men in the study’s MRI group were able to 
avoid biopsy when their imaging was negative on can-
cer imaging.
This has subsequently led to a new diagnostic para-
digm that implements mp-MRI test before even con-
sidering biopsy. Biopsy-naive men with clinical suspi-
cion of prostate cancer should according to new guide-
lines be first sent to mp-MRI testing based on which 
further diagnostic work-up can be determined. Sum-
mary of the changes in the EAU Guidelines are shown 
in Table 1.
While recent guidelines suggest a novel diagnostic 
pathway using mp-MRI before other diagnostic proce-
dures, one should consider limitations to these proofs 
and barriers that prevent a widespread use of the 
mp-MRI.
Limitations of Evidence
There are some challenges to accepting mp-MRI as 
the new standard of care in prostate cancer diagnosis. 
Although PRECISION trial does provide excellent 
data on mp-MRI, some important questions remain 
unanswered. As previously stated, one of the main 
findings is that 28% of men in the mp-MRI group 
avoided biopsy, reducing the risk of biopsy complica-
tions (sepsis, overdiagnosis etc.). But, as the authors of 
the study themselves acknowledged, there is no long-
term follow-up for these men, and estimates from lit-
erature suggest that negative predictive value was 67-
88%, meaning that 12% to 33% of those not biopsied 
harbor high-grade disease (10). Furthermore, PRECI-
SION demonstrates 5.5% absolute risk benefit of 
MRI-targeted biopsy for detecting the most aggres-
sive cancers (grade group 4 and 5). Their interpretation 
of this finding is that although mp-MRI may indeed 
lead to some missed high-grade tumors in patients 
with false-negative imaging results, this is more than 
counterbalanced for by the extra high-grade tumors 
that would be missed by systematic biopsy but that are 
identified by targeting MRI lesions. As critical edito-
rial in Jama Oncology states, this assumption of onco-
logic equivalence of high-grade tumors not visible on 
mp-MRI and high-grade tumors missed by systematic 
Table 1. Summary of recommendation changes  
in the EAU Guidelines from 2014 to 2019.
Year Recommendation for imaging LE GR
2014. When available mp-MRI  
can be used for targeted repeated 
prostate biopsy
2b B
2017. Perform multiparametric magnetic 
resonance imaging (mp-MRI) 
before repeated biopsy when 
clinical suspicion of PCa persists 
in spite of negative biopsies.
1a Strong
2019. Recommendations in biopsy-naive 
patients
Perform mp-MRI before prostate 
biopsy. 
1a Weak
2019. Recommendations in patients 
with prior negative biopsy
Perform mp-MRI before prostate 
biopsy. 
1a Strong
LE-level of evidence, GR, grade of recommendation
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biopsy is yet to be proved. (11). Some evidence actu-
ally suggest that this was not the case. Cumulative in-
cidence of prostate cancer–specific death after 15 years 
was 0.7% in patients with a negative biopsy result and 
PSA less than 10 ng/ml in Danish cancer registry and 
this cohort is very similar to PRECISION (11). This 
suggests that high-grade cancers missed by systematic 
biopsy but targeted by mp-MRI are unlikely to be ag-
gressive. On the contrary, the oncologic relevance of 
high-grade tumors that do not appear on mp-MRI is 
yet to be fully characterized. Hence, one must consider 
the drawbacks of these data.
Barriers to Implementing mp-MRI
There are several practical barriers that must be 
bridged before mp-MRI can be implemented in rou-
tine practice. Costs, availability and radiology expertise 
could hinder the implementation of mp-MRI as the 
primary diagnostic tool for prostate cancer. It is esti-
mated that by 2020, costs of prostate cancer care in the 
United States alone will increase to $16.3 billion (12). 
Obtaining an mp-MRI for every man with an elevated 
PSA level with a mean cost of mp-MRI of $2550 will 
sharply accelerate this increase. There are approximate-
ly 1.0 - 1.2 million prostate biopsies performed annu-
ally in the United States which means that introduc-
tion of mp-MRI prior to biopsy would contribute $3 
billion annually.
Despite serious costs almost all academic centers in 
USA perform prostate MRI. On the other hand, only 
30% of community hospitals do so (13). Furthermore, 
only 75% of hospitals perform less than 20 mp-MRIs 
monthly, with substantial heterogeneity in mp-MRI 
protocols (13). Interobserver variability between com-
munity hospitals and high-volume academic hospitals 
is substantial and agreement is only 54%. If high stan-
dards and accuracy of the test cannot be guaranteed 
across the country, then the value of the test is ques-
tionable.
Situation in Croatia
In a previously reported prospective study, we ana-
lyzed diagnostic utility and cost-benefit effect of intro-
ducing mp-MRI in diagnostic pathway for prostate 
cancer in Croatia (14,15). According to contemporary 
guidelines of that time, the study was designed for pa-
tients with indication for mp-MRI in repeated biopsy 
setting. With the advent of new guidelines recommen-
dation, the cost-benefit effect should be recalculated. 
Regarding availability, mp-MRI is available in 
most university hospitals and some county hospitals 
and privately led health practices. In the state-owned 
facilities the waiting list is 6 months or more while in 
private settings it is 1-2 weeks. Availability of mp-
MRI in September 2019 across the country is present-
ed in Figure 1.
European Association of Urology’s Position paper 
on screening for prostate cancer
On January 22nd, 2019 policy makers, scientific ex-
perts, patient groups’ representatives with an interest in 
prostate cancer gathered at the European Parliament 
to debate the latest evidence and case studies demon-
strating the efficacy of prostate cancer screening. It has 
been stated that prostate cancer mortality has over-
ruled colorectal cancer and is now the second most 
common cause of cancer-related death in men behind 
lung cancer. Still, despite the significant public health 
burden, relatively little is performed on prostate cancer 
screening at EU level.
Figure 1. shows availability of mp-MRI in 2019 across 
Croatia. White dots represent available mp-MRI, black 
dots unavailable mp-MRI of the prostate.
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However, there is evidence of reducing mortality by 
multiple rounds of PSA screening, the main obstacle 
in its implementation at a population level is a huge 
risk of overdiagnosis and overtreatment. Two large 
prospective trials, The European Randomized Study of 
Screening for Prostate Cancer (ERSPC) and the Pros-
tate, Long, Colorectal and Ovarian Cancer Screening 
Trial (PLCO), evaluated the role of PSA screening 
(16, 17). In ERSPC, at 16-year follow-up, PSA screen-
ing was associated with a relative reduction of 20% in 
cancer-specific mortality and the absolute difference 
in PCa mortality between trial arms increased from 
14% at 13 years to 18% at 16 years (16). In PLCO af-
ter almost 17 years of follow-up, no differences in 
mortality were detected between the two arms. PLCO 
was criticized for biased assessment of the efficacy of 
PSA screening as 80% of control arm received PSA 
testing at some point. When adjusted for these biases, 
it seems that PLCO results are consistent with ER-
SPC. Recent meta-analyses showed PSA screening 
leads to a small but significant reduction in the risk of 
dying from PCa over 10 years (19).
In 2019, reflecting the current knowledge about 
the effects of screening as well as major obstacles such 
as overdiagnosis and overtreatment, EAU has issued a 
Position paper (3).
There are several important statements in it:
Statement 1. Screening based on multiple PSA 
testing rounds reduces PCa-specific mortality in as-
ymptomatic men aged between 55 and 69 years.
Statement 2. Risk of overdiagnosis and overtreat-
ment represent the main barriers for the implementa-
tion of PSA screening policies at a population level.
Statement 3. A risk-adapted early detection strat-
egy based on PSA values at the age of 45 years should 
be offered to well-informed men with life expectancy 
of 10 years, where screening intervals should be indi-
vidualized according to baseline PSA levels.
Risk calculators based on PSA, family history, eth-
nicity, DRE, and prostate volume can assist physicians 
in the identification of men who should receive pros-
tate biopsy, reducing the risk of overdiagnosis.
Statement 4. Multiparametric MRI can safely im-
prove selection of men for prostate biopsy. The perfor-
mance of mp-MRI for PCa detection and risk estima-
tion is improved by using it in men at risk of clinically 
significant disease before prostate biopsy.
Statement 5. Novel tests based on biomarkers and 
genetic polymorphisms can improve the selection of 
men with significant PCa and reduce the number of 
unnecessary prostate biopsies and detection of insig-
nificant disease.
The EAU Position paper concludes that organized, 
population-based PSA screening programs should be 
implemented at a European level to reduce PCa mor-
tality, based on a risk-adapted strategy. This should in-
clude PSA testing of well-informed men beginning at 
the age of 45 years, in whom screening intervals should 
be individualized according to baseline PSA levels. 
They also include multiparametric MRI in the early 
detection pathway as a triage test to safely improve se-
lection of men for prostate biopsy. Risk calculators, 
biomarkers and genetic polymorphisms can further 
improve the identification of men with significant 
PCa and reduce the risk of overdiagnosis. The main 
tool to reduce the risk of overtreatment is an active 
surveillance in low-risk and some grade group 2 inter-
mediate-risk patients.
Future directions
New diagnostic pathway recommendations issued 
by the European Association of Urology pose a sig-
nificant challenge for many European urologists. This 
approach, both at individual and population level, 
comes at significant expense. It also takes significant 
time and resources, both material and human, espe-
cially regarding the implementation of MRI. Some 
countries are still not ready for the full implementation 
of these guidelines into routine clinical practice. Other 
tools such as biomarker tests, including free-to-total 
PSA ratio, Prostate Health Index, and the 4k score can 
help to further stratify up front need for an MRI and 
biopsy. This might, at the moment, bridge the lack of 
resources.
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Sažetak
DIJAGNOSTIKA RAKA PROSTATE U 2019. - PROMJENE U EUROPSKIM SMJERNICAMA  
I UTJECAJ NA SVAKODNEVNU PRAKSU
I. Tomašković, S. Nikles, M. Tomić, I. Pezelj i B. Ružić
Promjene u dijagnostici karcinoma prostate preporučene u najnovijim Smjernicama Europskog udruženja za urologiju 
donose mnoge izazove u svakodnevnoj praksi. Dostupnost, troškovi i pouzdanost slikovnog nalaza i dalje su izazov za usva-
janje ovih smjernica u svakodnevnoj kliničkoj praksi. U ovom članku raspravljamo o trenutnoj situaciji u Hrvatskoj i svijetu 
i o budućim opcijama.
Ključne riječi: karcinom prostate, smjernice, multiparametrijska magnetska rezonanca
